These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 20729914)
1. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents. Zenvirt S; Kravchenko-Balasha N; Levitzki A Oncogene; 2010 Nov; 29(46):6149-59. PubMed ID: 20729914 [TBL] [Abstract][Full Text] [Related]
2. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715 [TBL] [Abstract][Full Text] [Related]
3. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Xiao Z; Xue J; Sowin TJ; Zhang H Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813 [TBL] [Abstract][Full Text] [Related]
4. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells. Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205 [TBL] [Abstract][Full Text] [Related]
5. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188 [TBL] [Abstract][Full Text] [Related]
6. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1. Duan L; Perez RE; Hansen M; Gitelis S; Maki CG Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935 [TBL] [Abstract][Full Text] [Related]
7. Chk1 instability is coupled to mitotic cell death of p53-deficient cells in response to virus-induced DNA damage signaling. Jurvansuu J; Fragkos M; Ingemarsdotter C; Beard P J Mol Biol; 2007 Sep; 372(2):397-406. PubMed ID: 17663993 [TBL] [Abstract][Full Text] [Related]
8. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Smith J; Tho LM; Xu N; Gillespie DA Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966 [TBL] [Abstract][Full Text] [Related]
9. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676 [TBL] [Abstract][Full Text] [Related]
10. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cho SH; Toouli CD; Fujii GH; Crain C; Parry D Cell Cycle; 2005 Jan; 4(1):131-9. PubMed ID: 15539958 [TBL] [Abstract][Full Text] [Related]
11. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533 [TBL] [Abstract][Full Text] [Related]
13. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Jackson JR; Gilmartin A; Imburgia C; Winkler JD; Marshall LA; Roshak A Cancer Res; 2000 Feb; 60(3):566-72. PubMed ID: 10676638 [TBL] [Abstract][Full Text] [Related]
14. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202 [TBL] [Abstract][Full Text] [Related]
15. Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. Blackwood E; Epler J; Yen I; Flagella M; O'Brien T; Evangelista M; Schmidt S; Xiao Y; Choi J; Kowanetz K; Ramiscal J; Wong K; Jakubiak D; Yee S; Cain G; Gazzard L; Williams K; Halladay J; Jackson PK; Malek S Mol Cancer Ther; 2013 Oct; 12(10):1968-80. PubMed ID: 23873850 [TBL] [Abstract][Full Text] [Related]
17. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022 [TBL] [Abstract][Full Text] [Related]
18. Chk1 inhibitors for novel cancer treatment. Tao ZF; Lin NH Anticancer Agents Med Chem; 2006 Jul; 6(4):377-88. PubMed ID: 16842237 [TBL] [Abstract][Full Text] [Related]
19. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Lu X; Nannenga B; Donehower LA Genes Dev; 2005 May; 19(10):1162-74. PubMed ID: 15870257 [TBL] [Abstract][Full Text] [Related]
20. [Cell cycle regulation after exposure to ionizing radiation]. Teyssier F; Bay JO; Dionet C; Verrelle P Bull Cancer; 1999 Apr; 86(4):345-57. PubMed ID: 10341340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]